Method for producing mycosporine-like amino acid or precursor thereof
By culturing microorganisms with reduced amino acid metabolic enzymes, the method enhances the production and recovery of mycosporine-like amino acids, addressing inefficiencies in existing synthesis methods and offering effective UV protection solutions.
Patent Information
- Application Number
- PCT/JP2026/017632
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for producing mycosporine-like amino acids are inefficient and cumbersome, particularly through chemical synthesis, and there is a need for more effective microbial production pathways.
A method involving the culture of microorganisms with reduced or lost function of specific amino acid metabolic enzymes, such as proB, ltaA, cysM, pyrB, sda, purA, aspC, mgl, and cysA, to enhance the production and recovery of mycosporine-like amino acids or their precursors, utilizing microorganisms like Streptomyces lividans and Escherichia coli, and employing enzymes like demethyl-4-deoxygadusol synthase and O-methyltransferase.
This approach enables efficient production and recovery of mycosporine-like amino acids or their precursors, allowing for higher yields and reduced enzyme activity, suitable for various applications including UV protection.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Method for producing mycosporine-like amino acids or their precursors
[0001] This disclosure relates to a method for producing mycosporine-like amino acids or their precursors, and to microorganisms that produce them.
[0002] Ultraviolet (UV) radiation is a factor that causes skin inflammation, aging, and skin cancer, and is classified into UV-A (320-400 nm), UV-B (280-320 nm), and UV-C (200-280 nm) depending on the wavelength. Of these, UV-A and UV-B have an effect on living organisms, while UV-C is not a problem because it cannot normally pass through the atmosphere. Mycosporine-like amino acids (MAA) are natural UV-A absorbers that are widely known to be present in aquatic organisms such as corals, red algae, fish innards, and microalgae. Among them, cinolin is known to be the most effective natural UV-A absorber. Attempts have been made to produce mycosporine-like amino acids by chemical synthesis, but the process is long and complicated (Patent Document 1). It is known that mycosporine-like amino acids can be produced using microorganisms that produce mycosporine-like amino acids extracellularly (Patent Document 2), and the establishment of more efficient production methods is expected.
[0003] International Publication No. 2002 / 39974, International Publication No. 2015 / 174427
[0004] Bioscience, Biotechnology, and Biochemistry, Vol.82, No.7, 2018, pp.1252-1259J Org Chem. 2021 May 18;86(16):11160-11168.Appl Environ Microbiol. 2014 Mar;80(5):1763-1769.
[0005] The inventors have established a method for efficiently synthesizing mycosporin-like amino acids or their precursors by using microorganisms in which the function or expression of specific amino acid metabolic enzymes is reduced or lost.
[0006] A method for producing mycosporine-like amino acids or their precursors is provided, comprising the steps of culturing a microorganism capable of producing mycosporine-like amino acids or their precursors, and recovering mycosporine-like amino acids or their precursors from the culture, wherein the function or expression of one or more amino acid metabolic enzymes is reduced or lost in the microorganism. The disclosure provides, for example, the following: [Item 1] A method for producing mycosporine-like amino acids or their precursors, comprising the steps of culturing a microorganism capable of producing mycosporine-like amino acids or their precursors, and recovering mycosporine-like amino acids or their precursors from the culture, wherein the function or expression of one or more amino acid metabolic enzymes is reduced or lost in the microorganism. [Item 2] The method according to Item 1, further comprising the step of purifying the recovered mycosporine-like amino acids or their precursors. [Clause 3] The method of production according to Claim 1 or 2, wherein the one or more amino acid metabolic enzymes are selected from the group consisting of proB, ltaA, cysM, pyrB, sda, purA, aspC, mgl, cysA, and metB. [Clause 4] The method of production according to any one of Claims 1 to 3, wherein the one or more amino acid metabolic enzymes are selected from the group consisting of proB, ltaA, cysM, and pyrB. [Clause 5] The method of production according to Claim 4, wherein the one or more amino acid metabolic enzymes are proB, ltaA, or cysM. [Clause 6] The method of production according to any one of Claims 1 to 5, wherein the microorganism comprises a group of genes for mycosporine-like amino acids or their precursor biosynthesis enzymes. [Item 7] The method for producing mycosporine-like amino acids or their precursor biosynthetic enzymes, wherein the gene group comprises demethyl-4-deoxygadusol synthase, O-methyltransferase, and ATP Grasp family enzymes, and also comprises one or more selected from the group consisting of D-alanine-D-alanine ligase-like enzymes and non-ribosomal peptide synthases (NRPS).[Clause 8] The method for producing a mycosporine-like amino acid or a group of enzyme genes for the biosynthesis of its precursors, comprising at least demethyl-4-deoxygadusol synthase, O-methyltransferase, and ATP Grasp family enzymes and D-alanine-D-alanine ligase-like enzymes, according to Claim 6. [Clause 9] The method for producing a mycosporine-like amino acid, according to Claim 8, wherein the microorganism is Streptomyces lividans or Streptomyces evermethyls. [Clause 10] The method for producing a mycosporine-like amino acid, according to any one of Claims 1-9. [Clause 11] The method for producing a mycosporine-like amino acid, according to any one of Claims 1-10, wherein the mycosporine-like amino acid is synolin, porphyra-334, mycosporin lysine-alanine (MGA), or mycosporin lysine (MG). [Clause 12] The method for producing a mycosporine-like amino acid, wherein the precursor is 4-deoxygadusol, sedoheptulose-7-phosphate, or demethyl-4-deoxygadusol. [Clause 13] The method for producing a mycosporine-like amino acid, wherein the precursor is 4-deoxygadusol. [Clause 14] The method for producing a microorganism, wherein the microorganism is a microorganism belonging to the genus Streptomyces or Escherichia. [Clause 15] The method for producing a microorganism, wherein the microorganism belonging to the genus Escherichia is Escherichia coli. [Clause 16] The method for producing a microorganism, wherein the microorganism is a microorganism belonging to the genus Streptomyces or Escherichia. [Clause 17] The method for producing the microorganism according to any one of Claims 1-16, comprising the step of culturing the microorganism in a medium containing glucose, fructose, galactose, or mannose as a carbon source. [Clause 18] The method for producing the microorganism according to any one of Claims 1-17, comprising the step of culturing the microorganism in a medium containing glucose as a carbon source. [Clause 19] The method for producing the enzyme according to any one of Claims 1-18, wherein the enzyme activity of the enzyme is 10% or more, and 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15% or less, compared to the wild type or non-mutant.[Clause 20] The method for producing the enzyme according to any one of claims 1-19, wherein the enzyme activity of the enzyme is less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.03%, less than 0.02%, or less than 0.01% compared to the wild type or non-mutant. [Clause 21] The method for producing the enzyme according to any one of claims 1-20, wherein the transcription or translation level of the gene encoding the enzyme is 10% or more, and 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15% or less compared to the wild type or non-mutant. [Clause 22] The method of production according to any one of Clauses 1-21, wherein the level of transcription or translation of the gene encoding the enzyme is less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.03%, less than 0.02%, or less than 0.01%, compared to the wild type or a non-mutant.
[0007] According to this disclosure, mycosporine-like amino acids or their precursors can be efficiently obtained.
[0008] One aspect of the present disclosure provides a method for producing mycosporine-like amino acids or their precursors, comprising the steps of culturing a microorganism capable of producing mycosporine-like amino acids or their precursors, and recovering mycosporine-like amino acids or their precursors from the culture, wherein the function or expression of one or more amino acid metabolic enzymes is reduced or lost in the microorganism.
[0009] In this disclosure, "mycosporine-like amino acid" is a general term for compounds in which an amino acid is bonded to a cyclohexenone or cyclohexenimine skeleton, which may have substituents. Furthermore, in this disclosure, "precursor of mycosporine-like amino acid" refers to a compound that may be involved in the production of mycosporine-like amino acids in the biosynthetic pathway of mycosporine-like amino acids.
[0010] Mycosporine-like amino acids include, but are not limited to, synolin, porphyra-334, mycosporine-glycine-alanine, asterina-330, pariten, paritin, mycosporine-glycine (MG), mycosporine-glycine:valine, and mycosporine serinol. Those skilled in the art will understand, based on the contents of this disclosure and the results obtained, that other mycosporine-like amino acids can be obtained by appropriately controlling the expression of enzymes in the biosynthetic pathway, changing substrates, adjusting culture conditions, or introducing biosynthesis-related genes. For example, if the amount of synolin biosynthesis increases in the examples of this disclosure, those skilled in the art will recognize that the accumulation of the corresponding intermediate is occurring in that process. Based on this understanding, the amount of porphyra-334 produced can be increased instead of synolin by introducing the biosynthetic gene for porphyra-334, which branches off from the synolin synthesis pathway. Similarly, by introducing the mycosporine-glycine-alanine biosynthesis gene, it is also possible to increase the production of mycosporine-glycine-alanine instead of cinolin. Therefore, the technical scope of this disclosure is not limited to the mycosporine-like amino acids shown in the examples, but also extends to other mycosporine-like amino acids that can be obtained based on the technical knowledge of those skilled in the art. Examples of precursors of mycosporine-like amino acids include, but are not limited to, 4-deoxygadusole, sedoheptulose-7-phosphate, and demethyl-4-deoxygadusole. The accumulation of sedoheptulose-7-phosphate may be increased for the biosynthesis of mycosporine-like amino acids or their precursors. Methods for increasing the accumulation of sedoheptulose-7-phosphate include, but are not limited to, attenuating or disrupting the transaldolase gene (tal), introducing or enhancing the expression of genes involved in the pentose phosphate pathway upstream of sedoheptulose-7-phosphate, or attenuating or disrupting enzyme genes in glycolysis. Those skilled in the art can appropriately select or combine these methods depending on the purpose.Those skilled in the art will understand, based on the contents of this disclosure and the results obtained, that other mycosporine-like amino acids or their precursors can be obtained by appropriately controlling the expression of enzymes in the biosynthetic pathway, changing substrates, adjusting culture conditions, or introducing biosynthesis-related genes.
[0011] In this disclosure, "microorganisms" include, but are not limited to, bacteria such as actinomycetes, Escherichia coli and Bacillus subtilis, fungi such as molds and yeasts, microalgae such as Cyanobacteria, and Labyrinthules.
[0012] In this disclosure, "actinomycetes" refers to Gram-positive eubacteria belonging to the phylum Actinobacteria. Actinomycetes include, for example, Streptomyces species such as Streptomyces lividans, Streptomyces violaceoruber, Streptomyces coelicor, Streptomyces avermitilis, and Streptomyces griseus, as well as Actinosynnema pretiosum and Actinosynnema mirum. This includes the genera Actinosynnema (such as Actinocardia mirum), the genera Pseudocardia (such as Pseudocardia autotropica and Pseudocardia thermophylla), and the genera Corynebacterium (such as Corynebacterium glutamicum). Actinomycetes can be isolated, for example, from soil, and can also be obtained from microbial depository institutions.
[0013] The term "yeast" includes ascomycete yeasts, basidiospore-forming yeasts, and yeasts belonging to the imperfect fungi. For example, the genera Saccharomyces such as Saccharomyces cerevisiae, the genera Schizosaccharomyces such as Schizosaccharomyces pombe, the genera Phaffia such as Phaffia rhodozyma, the genera Kluyveromyces such as Kluyveromyces marxianus, and Yarrowia liporitica This includes the genera Yarrowia (such as *Yarrowia lipolytica*), the genera Pichia (such as *Pichia stipitis*), and the genera Candida (such as *Candida utilis*). Yeast can be isolated from plants, animals, soil, etc., and can also be obtained from microbial depository institutions.
[0014] "Microalgae" refers to algae with microscopic structures, excluding multicellular organisms such as seaweed from the broader category of algae. "Algae" refers to all organisms that perform oxygen-producing photosynthesis, excluding mosses, ferns, and seed plants that mainly inhabit land. Algae include various single-celled and multicellular organisms. For example, they include seaweed, the prokaryotes cyanobacteria, and the eukaryotes Glaucopodium, Rhodophyta, and Chlorophyta. Some microalgae are composed of multiple cells that form colonies. Furthermore, they do not necessarily inhabit water; some live in soil or on the surface of animals. "Cyanobacteria" includes, for example, Anabaena variabilis, Nostoc punctiforme, Nostoc linkia, Nostoc commune, Nostoc verrucosum, and Nostoc muscorum. Cyanobacteria can be isolated from nature, for example, or obtained from microbial depository institutions.
[0015] Labyrinthuria are amoeba-like eukaryotes belonging to the stramenopiles. Examples of Labyrinthuria include the genera Aurantiochytrium, Schizochytrium, Thraustochytrium, and Ulkenia. Labyrinthuria can be isolated from nature, such as from seaweed and terrestrial plants, and can also be obtained from microbial depository organizations.
[0016] In this disclosure, "microorganisms capable of producing mycosporine-like amino acids or their precursors" refers to microorganisms that have the ability to biosynthesize and produce mycosporine-like amino acids or their precursors, for example, microorganisms that have a gene for a mycosporine-like amino acid or its precursor biosynthesis enzyme. These "microorganisms capable of producing mycosporine-like amino acids or their precursors" may be wild-type strains or strains that have been artificially mutated. Examples of artificial mutagenesis include genetic recombination, UV irradiation, X-ray irradiation, and treatment with mutagens. Furthermore, microorganisms capable of producing mycosporine-like amino acids or their precursors may be spontaneously occurring mutant strains. "Microorganisms capable of producing mycosporine-like amino acids or their precursors" also include microorganisms that have a gene for a mycosporine-like amino acid or its precursor biosynthesis enzyme derived from the same or different species. For example, a microorganism into which a gene for a mycosporine-like amino acid or its precursor biosynthesis enzyme derived from a different species has been introduced by genetic recombination may be used. Methods widely known in the art can be used to introduce heterologous genes into the microorganisms described above. In this disclosure, whether or not a microorganism "has the ability to produce mycosporin-like amino acids or their precursors" can be determined by methods known to those skilled in the art. For example, it can be confirmed by detecting the target mycosporin-like amino acid or its precursor or biosynthetic intermediate using liquid chromatography, mass spectrometry, ultraviolet absorption spectroscopy, or a combination thereof, with culture medium, bacterial cells, extracellular culture medium, or culture supernatant as a sample. In addition, such production ability may be estimated or confirmed based on the presence of gene groups involved in the biosynthesis of the target compound, the expression of such gene groups, or the presence of corresponding enzyme activity, in addition to the actual measurement of the target compound.
[0017] When introducing mycosporin-like amino acids or their precursor biosynthetic enzyme genes, whether of the same or different origin, into microorganisms by genetic recombination, for example, a promoter, a 5' untranslated region (UTR), a transformant selection marker gene, a 3' untranslated region (UTR), or a part thereof may be introduced together with the gene. In this case, promoters and the like, which are widely known to those skilled in the art as being used in each microorganism, may be used. Furthermore, the codons of the gene may be appropriately modified depending on the codon usage frequency of the microorganism into which the mycosporin-like amino acid or its precursor biosynthetic enzyme gene is introduced. Those skilled in the art can investigate the codon usage frequency of a certain microorganism, for example, using the Kazusa DNA Research Institute's database, Codon Usage Database (http: / / www.kazusa.or.jp / codon / ). Alternatively, codon usage frequency can be investigated using GENEART's gene sequencing design program, GeneOptimizer®, or similar. Furthermore, based on the codon usage frequency information obtained in this way, the codons of the target gene can be optimized using conventional methods.
[0018] Mycosporin-like amino acids or their precursor biosynthetic enzyme genes include, for example, the amir_4256 (SEQ ID NO: 1), amir_4257 (SEQ ID NO: 2), amir_4258 (SEQ ID NO: 3), and amir_4259 (SEQ ID NO: 4) genes from Actinosynnema mirum DSM43827 (Non-Patent Literature 1), and Pseudonocardia sp. The genes pseP1_010100031425 (SEQ ID NO: 5), pseP1_010100031430 (SEQ ID NO: 6), pseP1_010100031435 (SEQ ID NO: 7), pseP1_010100031440 (SEQ ID NO: 8) derived from P1, the genes Ava_3855, Ava_3856, Ava_3857, and Ava_3858 derived from Anabaena variabilis ATCC29413 (see Balskus EP et al., Science, (2010), 329:1653-1656), and Nostoc punctiforme. Examples include, but are not limited to, the mysA, mysB, mysC, and mysD genes derived from ATCC29133 (see JOURNAL OF BACTERIOLOGY, Nov. 2011, Vol. 193, No. 21, pp. 5923-5928). For example, when labyrinthula species are used, in one embodiment, codon-modified amir_4256 (SEQ ID NO: 9), codon-modified amir_4257 (SEQ ID NO: 10), codon-modified amir_4258 (SEQ ID NO: 11), and codon-modified amir_4259 (SEQ ID NO: 12) genes are used as mycosporine-like amino acid or precursor biosynthesis enzyme genes.
[0019] Enzymes and corresponding genes involved in the biosynthesis of mycosporine-like amino acids or their precursors include, but are not limited to, the following: Demethyl 4-deoxygadusol (DDG) synthase converts sedoheptulose-7-phosphate to DDG. For example, the protein encoded by the amir_4259 gene is included, but is not limited to. DDG is converted to 4-deoxygadusol (4-DG) by O-methyltransferase (O-MT). For example, the protein encoded by the amir_4258 gene is included, but is not limited to. 4-DG is then converted to mycosporine-glycine (MG) by enzymes belonging to the ATP-grasp family. For example, the protein encoded by the amir_4257 gene is included, but is not limited to. When amino acids are added to mycosporin-glycine by a D-alanine-D-alanine ligase-like enzyme or a non-ribosomal peptide synthase (NRPS), different products are obtained depending on the type of amino acid added. Specifically, when serine is added, cinorine is produced; when threonine is added, porphyra-334 is produced; when alanine is added, mycosporin-glycine:alanine is produced; and when glycine is added, mycosporin-glycine:glycine is produced. For example, the genes encoding the enzyme that produces cinorine include, but are not limited to, the amir_4256 gene (Non-Patent Literature 1) and the ava_3855 gene. For example, the gene encoding the enzyme that produces porphyra-334 includes, but is not limited to, the NIES25_64160 gene (Non-Patent Literature 2). For example, the gene encoding the enzyme that produces mycosporin-glycine:glycine includes, but is not limited to, the ap_3855 gene (Non-Patent Literature 3). Those skilled in the art can appropriately select genes for the biosynthesis of a desired mycosporine-like amino acid or its precursor, taking into consideration the biosynthetic pathway of the mycosporine-like amino acid or its precursor.
[0020] According to the method of this disclosure, mycosporine-like amino acids or their precursors can be obtained from a culture. In one embodiment, mycosporine-like amino acids or their precursors may be recovered from the culture. The culture may include bacterial cells, extracellular culture medium, or a combination thereof. When mycosporine-like amino acids or their precursors are recovered from the culture medium, it is preferable because it eliminates the need for a step to disrupt the microorganisms, thus reducing time or costs.
[0021] In one embodiment, the microorganism of this disclosure may have the property of transporting the mycosporin-like amino acids or their precursors outside the cell. For example, the microorganism may have a transporter that transports mycosporin-like amino acids or their precursors outside the cell. The transporter may be endogenous or exogenous. The type of transporter is not particularly limited and includes, but is not limited to, membrane transporters, efflux pumps, MFS transporters, ABC transporters, and other proteins that may be involved in the extracellular transport of small molecules. The gene encoding the transporter may be introduced into the host microorganism, or the expression of a corresponding gene endogenous in the host microorganism may be enhanced.
[0022] In this disclosure, "bacterial cells" refers to the cells of a microorganism. In this disclosure, "extracellular culture medium" refers to the portion of the culture medium obtained by culturing a microorganism, excluding the microbial cells. That is, the extracellular culture medium contains various components contained in the culture medium used for cultivation, substances produced by the microorganism during cultivation, etc.
[0023] The method for separating the bacterial cells from the extracellular culture medium can be appropriately selected by those skilled in the art. For example, the bacterial cells and extracellular culture medium may be separated by centrifuging the culture medium obtained by culturing microorganisms. The conditions for centrifugation, such as temperature, time, and speed, can be those well known to those skilled in the art, depending on the type of microorganism used. Alternatively, the bacterial cells and extracellular culture medium may be separated by filtering the culture medium obtained by culturing microorganisms using a suitable filtration membrane. Furthermore, the bacterial cells may be agglutinated using a suitable flocculant before centrifugation or filtration.
[0024] The recovery of mycosporine-like amino acids or precursors thereof from bacterial cells refers to recovering the mycosporine-like amino acids or precursors thereof contained in the bacterial cells. This includes operations of removing other components contained in the bacterial cells, such as microorganism-derived proteins, nucleic acids, lipids, and medium-derived residues, to obtain a solution mainly containing the mycosporine-like amino acids or precursors thereof. The method for recovering mycosporine-like amino acids or precursors thereof from bacterial cells is also appropriately selected by those skilled in the art. For example, mycosporine-like amino acids or precursors thereof can be recovered by performing centrifugation, filtration, extraction and the like after disrupting the bacterial cells. The extraction medium to be used is also appropriately selected by those skilled in the art. In a preferred embodiment, an aqueous medium is used. Examples of the aqueous medium include, but are not limited to, acidic, neutral or alkaline aqueous solutions, or aqueous solutions containing salts.
[0025] The recovery of mycosporine-like amino acids or precursors thereof from the extracellular culture solution refers to recovering the mycosporine-like amino acids or precursors thereof contained in the extracellular culture solution. This includes operations of removing various components contained in the medium used for culture, substances other than the mycosporine-like amino acids or precursors thereof produced by the microorganism during culture, and the like, to obtain a solution mainly containing the mycosporine-like amino acids or precursors thereof. The method for recovering mycosporine-like amino acids or precursors thereof from the extracellular culture solution is also appropriately selected by those skilled in the art. For example, mycosporine-like amino acids or precursors thereof can be recovered from the extracellular culture solution by filtration through a membrane or using an appropriate medium. The medium is appropriately selected by those skilled in the art. In a preferred embodiment, an aqueous medium is used. Examples of the aqueous medium include, but are not limited to, acidic, neutral or alkaline aqueous solutions, or aqueous solutions containing salts.
[0026] In another embodiment, the present disclosure provides the method of the present disclosure described above, further comprising the step of purifying the recovered mycosporine-like amino acid or a precursor thereof. For the purification of the mycosporine-like amino acid or a precursor thereof, methods well known to those skilled in the art for purifying metabolites from microbial cultures can be used. For example, extraction with an organic solvent, activated carbon treatment, gel filtration, ion exchange column chromatography, high performance liquid chromatography (HPLC), crystallization, electrodialysis and the like may be used to obtain the purified mycosporine-like amino acid or a precursor thereof.
[0027] In the present disclosure, the medium may be neutralized as necessary. Known neutralizing agents may be used, for example, carbonates such as calcium carbonate, magnesium carbonate, sodium carbonate and sodium bicarbonate, hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide and magnesium hydroxide, ammonia, quicklime, limestone, slaked lime and the like are used. In certain embodiments, the neutralizing agent used in the present disclosure is a carbonate such as calcium carbonate, magnesium carbonate, sodium carbonate and sodium bicarbonate. The neutralizing agent may be added to the medium before culturing, or may be added during culturing. Further, the addition of the neutralizing agent may be continuous or intermittent. The addition amount of the neutralizing agent can be easily determined by measuring the pH of the medium. The pH can be measured by a conventionally known method, for example, using a pH meter.
[0028] In the present disclosure, the medium for culturing microorganisms and other culture conditions (temperature, time, pH, presence or absence of agitation, etc.) can be appropriately selected by a person skilled in the art according to the type of microorganism to be cultured. In the present disclosure, the carbon source is not particularly limited, but sugars, organic acids, alcohols, fatty acids and the like may be used. As for the carbon source to be used, examples of sugars include, but are not limited to, monosaccharides, disaccharides, and other oligosaccharides. Examples of hexose monosaccharides include glucose, fructose, galactose, and mannose. Examples of pentose monosaccharides include xylose, arabinose, ribulose, and ribose. Examples of disaccharides include lactose, sucrose, maltose, and trehalose. In addition, examples of sugars include sugar alcohols such as sorbitol, mannitol, and inositol. As the carbon source, lower alcohols such as glycerol and ethanol may be used, and as organic acids, acetic acid, lactic acid, citric acid, succinic acid, pyruvic acid, malonic acid, gluconic acid and the like may be used. From the viewpoint of microbial growth, it is preferable to use glucose as the carbon source.
[0029] When actinomycetes are used, for example, a semi-synthetic medium for actinomycetes (6% glucose, 0.2% NaCl, 0.05% K 2 HPO 4 , 0.01% MgSO 4 ·7H 2 O, 0.2% (NH 4 ) 2 SO 4 , 0.2% yeast extract, 0.005% FeSO 4 ·7H 2 O, 0.005% MnSO 4 ·4H 2 O, 0.005% ZnSO 4 ·7H 2 O, 0.5% CaCO 3 ), TSB medium (0.25% glucose, 1.7% pancreatic digest of casein, 0.3% papaic digest of soybean, 0.5% NaCl, 0.25% K 2 HPO 4 ), or SYN medium (0.7% casamino acid, 0.2% yeast extract, 0.264% (NH 4 ) 2 SO 4 , 0.238% KH2 PO 4 , 0.556% K 2 HPO 4 , 0.1% MgSO 4 7H 2 O, 0.0064% CuSO 4 ・5H 2 O, 0.0011% FeSO 4 7H 2 O, 0.0079% MnSO 4 4H 2 O, 0.0015% ZnSO 4 7H 2 O, 0.5% CaCO 3 ) may be used. When using E. coli, for example, LB medium, 2×YT medium, NZY medium, M9 medium, SOC medium, or YPD medium may be used. When using yeast, for example, SD medium, YPD medium, or YPAD medium may be used.
[0030] The above culture medium may be modified as appropriate to improve microbial culture. For example, by increasing the initial glucose concentration in the medium, or by using Trace element solution (×200) (CuSO4). 4 ・5H 2 O 64mg, FeSO 4 7H 2 O 11mg, MnSO 4 4H 2 O 79mg, ZnSO 4 7H 2 The culture medium may be modified by adding 15 mg / 50 mL of O.
[0031] Conventional methods can be used to identify mycosporine-like amino acids or their precursors. For example, high-performance liquid chromatography-time-of-flight mass spectrometry (HPLC-TOFMS) may be used to identify mycosporine-like amino acids. Similarly, conventional methods can be used to identify novel mycosporine-like amino acids. For example, novel mycosporine-like amino acids may be identified by combining high-resolution mass spectrometry (HR-MS) and nuclear magnetic resonance (NMR). Alternatively, mycosporine-like amino acids may be identified using HPLC based on retention time and UV spectrum results. Or, novel mycosporine-like amino acids may be identified by measuring the ultraviolet absorption spectrum and precise mass using an HPLC equipped with a photodiode array detector and an HR-MS detector.
[0032] Microorganisms cultured in the method for producing mycosporine-like amino acids or their precursors according to this disclosure exhibit reduced or lost function or expression of one or more amino acid metabolic enzymes. Examples of genes encoding amino acid metabolic enzymes with reduced or lost function or expression include, but are not limited to, the glutamate 5-kinase gene, threonine aldolase gene, cystathionine β-synthase gene, and aspartate carbamoyltransferase catalytic subunit gene, serine dehydratase gene, adenylosuccinate synthase gene, aspartate aminotransferase gene, methionine γ-lyase gene, cystathionine γ-lyase gene, and cystathionine γ-synthase gene. Examples of glutamate 5-kinase genes, threonine aldolase genes, cystathionine β-synthase genes, and aspartate carbamoyltransferase catalytic subunit genes, serine dehydratase genes, adenylosuccinate synthase genes, aspartate aminotransferase genes, methionine γ-lyase genes, cystathionine γ-lyase genes, and cystathionine γ-synthase genes include, but are not limited to, proB, ltaA, cysM, pyrB, sda, purA, aspC, mgl, cysA, and metB, respectively. Examples of proB, ltaA, cysM, pyrB, sda, purA, aspC, mgl, cysA, and metB include, but are not limited to, SLI_2924, SLI_1361, SLI_3427, SLI_1784, SLI_5738, SLI_3874, SLI_4916, SLI_1576, SLI_4178, and SLI_5230, respectively. It is preferable that the function or expression of the glutamine synthetase gene, acetylglutamate kinase gene, or asparagine synthetase gene is not attenuated or lost in the microorganism cultured in the method for producing mycosporine-like amino acids or their precursors according to this disclosure. Examples of glutamine synthetase genes, acetylglutamate kinase genes, or asparagine synthetase genes include glnA, argB, and asns, respectively.Examples of glnA, argB, and asns include SLI_2525, SLI_1881, and SLI_0344, respectively.
[0033] In this disclosure, “amino acid metabolic enzyme” means an enzyme involved in the metabolism of amino acids, and may, for example, be an enzyme involved in the biosynthetic or degradation pathway of amino acids. In this disclosure, “amino acid metabolic enzyme” includes, but is not limited to, enzymes that catalyze reactions such as the transfer, elimination, addition, oxidation-reduction, hydrolysis, phosphorylation, and dephosphorylation of amino groups in amino acids themselves, amino acid precursors, or amino acid metabolites. Examples of amino acid metabolic enzymes include, but are not limited to, transferases, deaminases, decarboxylases, carboxylases, oxidases, hydroxylases, peptidases, kinases, phosphatases, aldolases, isomerases, synthases, and synthetases. In this disclosure, one or more amino acid metabolic enzymes selected from the group consisting of proB, ltaA, cysM, and pyrB may be cited as having reduced or lost function or expression, but is not limited to these. In a preferred embodiment, the amino acid metabolic enzyme whose function or expression is reduced or lost is preferably one or more selected from the group consisting of proB, ltaA, and cysM. In a more preferred embodiment, the amino acid metabolic enzyme whose function or expression is reduced or lost is proB, ltaA, or cysM. In the most preferred embodiment, the function or expression of proB is reduced or lost. In this most preferred embodiment, in addition to the reduction in the function or expression of proB, the function or expression of ltaA and / or cysM may also be reduced or lost.
[0034] In this disclosure, "reduced function" means a state in which the catalytic activity of the enzyme toward a substrate that it originally possesses is reduced compared to the wild type or non-mutant. For example, the enzyme activity may be 10% or more, and 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15% or less, compared to the wild type or non-mutant.
[0035] In this disclosure, "loss of function" means a state in which the enzyme exhibits little to no catalytic activity toward the substrate that it originally possesses, and may be, for example, less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.03%, less than 0.02%, or less than 0.01% compared to the wild type or non-mutant. When "loss of function" occurs, the catalytic activity of the enzyme is also limited to the activity below the detection limit. For example, it is known that SLI_2924 of Streptomyces lividance becomes proline-requiring by the A649C base substitution.
[0036] In this disclosure, "reduced expression" means a state in which the transcription or translation level of the gene encoding the enzyme is reduced, and the transcription or translation level may be, for example, 10% or more of mRNA or protein quantity compared to the wild type or non-mutant, and 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15% or less.
[0037] In this disclosure, “loss of expression” means that the gene encoding the enzyme is not transcribed or translated, or is transcribed or translated only at a very low level, including, for example, when the enzyme is undetectable or functionally negligible, and the level of transcription or translation may be, for example, less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.03%, less than 0.02%, or less than 0.01% compared to the wild type or non-mutant. “Loss of expression” includes cases where the level of transcription or translation is below the detection limit.
[0038] In one embodiment, the function of the enzyme may be controlled by the DNA sequence encoding the protein, by the transcription stage of the DNA sequence encoding the protein, by the translation stage of the protein, or by a post-translational stage of the protein. Preferably, the function of the enzyme is controlled by the DNA sequence encoding the protein. In another embodiment, the function of the enzyme may be controlled by the DNA sequence encoding the protein, and may be attenuated or lost, for example, by mutations in the DNA sequence encoding the protein. In yet another embodiment, the function of the enzyme may be controlled by the transcription stage of the DNA sequence encoding the protein, and may be attenuated or lost, for example, by alteration of the function of the cis-element or trans-element of the DNA sequence encoding the protein. In yet another embodiment, the function of the enzyme may be controlled by the translation stage of the protein, and may be attenuated or lost, for example, by mutations in the Shine-Dalgano sequence related to the translation of the protein. In yet another embodiment, the function of the enzyme may be controlled by a post-translational stage of the protein, and may be attenuated or lost, for example, by treatment with an inhibitor of the protein. Attenuation or loss of enzyme function or expression can be carried out by methods known to those skilled in the art, such as knockdown, knockout, or knock-in.
[0039] In this disclosure, “mutation” means a structural alteration of the sequence of a nucleic acid or protein, including substitutions, additions, deletions, or recombinations of bases or amino acids. These mutations may be spontaneous, induced, or artificially manipulated. In this disclosure, the reference sequence (comparison) used to determine the presence or absence of a mutation is not necessarily limited to the wild-type strain, but may be other known strains or other mutant strains. Therefore, a “mutation” in a given sequence includes any sequence change that differs from any comparison sequence.
[0040] A person skilled in the art can confirm, but is not limited to, that the function or expression of the enzyme is reduced or lost by confirming mutations in the gene encoding the protein, confirming the transcription of the gene encoding the protein, or confirming the activity or abundance of the protein, in accordance with the known art.
[0041] Microorganisms in which the function or expression of one or more amino acid metabolizing enzymes of this disclosure is attenuated or lost will produce increased mycosporine-like amino acids or their precursors compared to identical microorganisms, except that the function or expression of such enzymes is not attenuated or lost. For example, the increase may be 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2.0 times, 2.5 times, 3.0 times, 3.5 times, 4.0 times, 4.5 times, or 5.0 times or more.
[0042] In this disclosure, "about" means a range of ±10%, preferably ±5%, and more preferably ±2.5%.
[0043] The present disclosure will be described in detail below with reference to examples, but these examples are for illustrative purposes only and are not intended to limit the present disclosure.
[0044] [Example 1] Production of cinolin using a Streptomyces lividans gene-inactivated strain 1-1. Knockdown or disruption of amino acid metabolism genes The six genes listed in Table 1 of a Streptomyces lividans 1326 strain derivative (a strain of the 1326 strain in which genes involved in the synthesis of antibiotics and pigments have been disrupted, called the SM206 strain) were each knocked down or disrupted (referred to as gene-inactivated strains). Specifically, the gene sequences on the chromosome were replaced with a single nucleotide substitution sequence (A649C, SEQ ID NO: 13) for SLI_2924, which is known to cause loss of enzyme activity, and the remaining genes were replaced with drug resistance markers using conventionally known homologous recombination methods. For comparison, strains were created in which glnA, argB, or asns were disrupted as examples of disrupting other amino acid metabolism enzymes.
[0045] 1-2. Using transformed Streptomyces lividance 1326 strain derivatives and gene-inactivated strains as hosts, strains possessing plasmids expressing mycosporine-like amino acid biosynthesis genes were constructed. As synolin biosynthesis enzyme genes, amir_4256, amir_4257, amir_4258, and amir_4259 genes from Actinosynnema mirum DSM43827 were used (SEQ ID NOs: 1-4). These genes were each ligated to vectors having a pIJ101 origin under the control of the xylA promoter (J. Microbiol. Biotechnol. 2008 May; 18(5): 837-44) to construct plasmids expressing the genes. Plasmids expressing these genes were used to transform Streptomyces lividance 1326 derivatives and their gene-inactivated strains to obtain mycosporine-like amino acid producing strains. Transformation was carried out according to conventionally known methods.
[0046] 1-3. Pre-culture of mycosporine-like amino acid producing strains The glycerol stock of the mycosporine-like amino acid producing strain containing the mycosporine-like amino acid biosynthesis enzyme gene prepared in 1-2 was transferred to 10 mL of TSB medium supplemented with 50 g / L of glucose, and cultured with shaking at 30°C and 300 rpm for 3 days.
[0047] 1-4. Main culture of mycosporin-like amino acid producing strains 2.5 mL of pre-culture solution and 47.5 mL of culture medium (Table 2) were added to a 500 mL baffled flask, and the culture was incubated with shaking at 160 rpm and 30°C for 7 days. During the culture, solutions containing glucose and ammonium sulfate were added as needed to prevent depletion of carbon and nitrogen sources.
[0048] 1-5. Measurement of Synorine Production: 1 mL of culture medium was collected and centrifuged at 15,000 rpm for 10 minutes to obtain the culture supernatant. The amount of synorine in the culture supernatant was measured by UPLC. The UPLC measurement conditions are as shown in Table 3. The amount of synorine produced was converted to the concentration in 50 mL of culture medium, which was the initial amount of culture medium (sinoline measurement value × amount of culture medium at the time of collection (mL) / 50 mL).
[0049] 1-6. Results The results are shown in Table 4. When comparing the production of strains using the SM206 strain as the host for the gene expression plasmid (set to 1) with strains using gene-inactivated strains as the host, the proB-inactivated strain produced 2.0 times more, the cysM-inactivated strain produced 1.3 times more, and the ltaA-inactivated strain produced 1.3 times more. [Example 2] 2-1. Transformation of mycosporing lysin or its precursor biosynthesis enzyme gene group insertion plasmids Using the streptomyces lividance 1326 strain derivative and its proB gene inactivated strain constructed in 1-1 as hosts, strains possessing plasmids expressing mycosporing lysin (MG) or its precursor biosynthesis genes were created. As MG biosynthesis enzyme genes, amir_4257, amir_4258, and amir_4259 genes from Actinosynthema mirum DSM43827 were used (SEQ ID NOs: 2-4). As 4-deoxygadusol (4-DG) biosynthesis enzyme genes, the amir_4258 and amir_4259 genes from Actinosynthema mirum DSM43827 were used (SEQ ID NOs: 3, 4). These genes were each ligated to vectors having the pIJ101 origin under the control of the xylA promoter (J. Microbiol. Biotechnol. 2008 May; 18(5): 837-44) to construct plasmids expressing these genes. These plasmids were used to transform Streptomyces lividance 1326 derivatives and their gene-inactivated strains to obtain MG or 4-DG producing strains. Transformation was carried out according to conventionally known methods.
[0050] 2-2. Pre-culture of MG or 4-DG producing strains The glycerol stocks of mycosporine-like amino acid or 4-DG producing strains containing mycosporine-like amino acid or 4-DG biosynthesis enzyme genes, prepared in 2-1, were transferred to 10 mL of TSB medium supplemented with 50 g / L of glucose and cultured with shaking at 30°C and 300 rpm for 3 days.
[0051] 2-3. Main culture of MG or 4-DG producing strains 2.5 mL of pre-culture solution and 47.5 mL of culture medium (Table 5) were added to a 500 mL baffled flask, and the culture was incubated with shaking at 160 rpm and 30°C for 7 days. During the culture, solutions containing glucose and ammonium sulfate were added as needed to prevent depletion of carbon and nitrogen sources.
[0052] 2-4. Measurement of MG and 4-DG production: 1 mL of culture medium was collected and centrifuged at 15,000 rpm for 10 minutes to obtain the culture supernatant. The amounts of MG and 4-DG in the culture supernatant were measured by UPLC. The UPLC measurement conditions were as shown in Table 6 for MG and as shown in Table 7 for 4-DG. The amount of MG or 4-DG produced was converted to the concentration in 50 mL of culture medium, which was the initial culture volume (MG or 4-DG measurement value × volume of culture medium at the time of collection (mL) / 50 mL).
[0053] 2-5. Results The results are shown in Tables 8 and 9. Table 8 shows the results for the MG-producing strain, and Table 9 shows the results for the 4-DG-producing strain. When comparing the production of the strain using the SM206 strain as the host of the gene expression plasmid (set to 1) with the strain using the gene-inactivated strain as the host, the proB-inactivated strain showed a 2.2-fold increase in MG and a 1.6-fold increase in 4-DG. This indicates that production is increased upstream of mycosporine-like amino acids in the proB-inactivated strain.
[0054] [Example 3] Production of cinolin using a Streptomyces lividans gene-inactivated strain 3-1. Disruption of amino acid metabolism genes Based on the Streptomyces lividans TK64 strain, a strain was created in which the transaldolase gene (tal2, SLI_2249) was disrupted by a method similar to that described in International Publication WO2019 / 208747 (referred to as strain TK64-1). Next, a strain was created in which the serine dehydratase gene (sda) (SLI_5738) of strain TK64-1 was disrupted (referred to as strain TK64-2). Specifically, the substitution was carried out by a conventionally known homologous recombination method.
[0055] 3-2. Transformation of Mycosporine-like Amino Acid Biosynthesis Enzyme Insertion Plasmids Using the bacterial strain prepared in 3-1 as a host, strains possessing plasmids expressing mycosporine-like amino acid biosynthesis genes were created. As synolin biosynthesis enzyme genes, amir_4256, amir_4257, amir_4258, and amir_4259 genes from Actinosynnema mirum DSM43827 were used (SEQ ID NOs: 1-4). These genes were each ligated to vectors having a pIJ101 origin under the control of the xylA promoter (J. Microbiol. Biotechnol. 2008 May; 18(5): 837-44) to construct plasmids expressing the genes. These genes were expressed in plasmids to transform the TK64-1 strain, the TK64-2 strain, and their gene-inactivated strains to obtain mycosporine-like amino acid-producing strains. The transformation was carried out according to conventionally known methods.
[0056] 3-3. Pre-culture of mycosporine-like amino acid producing strains Glycerol stocks of mycosporine-like amino acid producing strains containing mycosporine-like amino acid biosynthesis enzyme genes, prepared in 3-2, were transferred to 10 mL of culture medium and cultured with shaking at 30°C and 300 rpm for 3 days.
[0057] 3-4. Main culture of mycosporin-like amino acid producing strains 2.5 mL of pre-culture solution and 47.5 mL of culture medium were added to a 500 mL baffled flask and cultured with shaking at 160 rpm and 30°C for 7 days. During the culture, solutions containing glucose and ammonium sulfate were added as needed to prevent depletion of carbon and nitrogen sources.
[0058] 3-5. Measurement of Synorine Production: 1 mL of culture medium was collected and centrifuged at 15,000 rpm for 10 minutes to obtain the culture supernatant. The amount of synorine in the culture supernatant was measured by UPLC. The UPLC measurement conditions are as shown in Table 10. The amount of synorine produced was converted to the concentration in 50 mL of culture medium, which was the initial amount of culture medium (sinoline measurement value × amount of culture medium at the time of collection (mL) / 50 mL).
[0059] 3-6. Results The results are shown in Table 11. When comparing the production of strains using the TK64-1 strain as the host of the gene expression plasmid (set to 1) with strains using the gene-inactivated strain as the host, the sda-inactivated strain (TK64-2 strain) produced 1.4 times more.
[0060] [Example 4] Production of cinolin using a Streptomyces lividans gene-inactivated strain 4-1. Knockdown of amino acid metabolism gene The Streptomyces lividans TK64 strain is a strain that possesses an inactivated proB gene (A649C single nucleotide substitution sequence of SLI_2924) and is known as a proline-requiring strain (Kieser, T., Bibb, MJ, Buttner, MJ, Chater, KF, and Hopwood, DA 2000. Practical Streptomyces Genetics. John Innes Foundation, Norwich, UK.). Therefore, the TK64-1 strain and its sda-inactivated strain (TK64-2 strain) produced in 3-1 are also strains that possess an inactivated proB gene. A strain (TK64-2_proB normalized strain) was created by replacing the inactivated proB gene of the TK64-2 strain with the normal proB gene (SLI_2924). Specifically, the replacement was performed using a conventionally known homologous recombination method.
[0061] 4-2. Transformation of Mycosporine-like Amino Acid Biosynthesis Enzyme Insertion Plasmids Using the bacterial strain prepared in 4-1 as a host, strains possessing plasmids expressing mycosporine-like amino acid biosynthesis genes were created. As synolin biosynthesis enzyme genes, amir_4256, amir_4257, amir_4258, and amir_4259 genes from Actinosynnema mirum DSM43827 were used (SEQ ID NOs: 1-4). These genes were each ligated to vectors having a pIJ101 origin under the control of the xylA promoter (J. Microbiol. Biotechnol. 2008 May; 18(5): 837-44) to construct plasmids expressing the genes. The TK64-2 strain and the TK64-2_proB normalized strain were transformed with plasmids expressing these genes to obtain mycosporine-like amino acid producing strains. The transformation was carried out according to conventionally known methods.
[0062] 4-3. Pre-culture of mycosporine-like amino acid producing strains The glycerol stock of the mycosporine-like amino acid producing strain containing the mycosporine-like amino acid biosynthesis enzyme gene prepared in 4-2 was transferred to 10 mL of TSB medium supplemented with 50 g / L of glucose, and cultured with shaking at 30°C and 300 rpm for 3 days.
[0063] 4-4. Main culture of mycosporine-like amino acid producing strains: Similar to Examples 1 and 2, 2.5 mL of pre-culture solution and 47.5 mL of culture medium were added to a 500 mL baffled flask and cultured with shaking at 160 rpm and 30°C for 7 days. During the culture, solutions containing glucose and ammonium sulfate were added as needed to prevent depletion of carbon and nitrogen sources.
[0064] 4-5. Measurement of Synorine Production: 1 mL of culture medium was collected and centrifuged at 15,000 rpm for 10 minutes to obtain the culture supernatant. The amount of synorine in the culture supernatant was measured by UPLC. The UPLC measurement conditions are shown in Table 12. The amount of synorine produced was converted to the concentration in 50 mL of culture medium, which was the initial amount of culture medium (sinoline measurement value × amount of culture medium at the time of collection (mL) / 50 mL).
[0065] 4-6. Results: When comparing the production of a strain using the proB normal strain (TK64-2_proB normalized strain) as the host of the gene expression plasmid (set to 1), the production of a strain using the proB inactivated strain (TK64-2 strain) as the host was 1.5 times higher with the proB inactivated strain.
[0066] [Example 5] Production of cinolin using Streptomyces lividance gene-inactivated strain 5-1. Disruption of amino acid metabolism genes Strains were prepared by disrupting purA (SLI_3874), aspC (SLI_4916), pyrB (SLI_1784), mgl (SLI_1576), cysA (SLI_4178), or metB (SLI_5230) from the TK64-2 strain prepared in Example 3-1. Specifically, each gene sequence on the chromosome was replaced with a drug resistance marker by a conventionally known homologous recombination method.
[0067] 5-2. Transformation of Mycosporine-like Amino Acid Biosynthesis Enzyme Insertion Plasmids Using the bacterial strain prepared in 5-1 as a host, strains possessing plasmids expressing mycosporine-like amino acid biosynthesis genes were created. As synolin biosynthesis enzyme genes, amir_4256, amir_4257, amir_4258, and amir_4259 genes from Actinosynnema mirum DSM43827 were used (SEQ ID NOs: 1-4). These genes were each ligated to vectors having a pIJ101 origin under the control of the xylA promoter (J. Microbiol. Biotechnol. 2008 May; 18(5): 837-44) to construct plasmids expressing the genes. The gene-inactivated strains constructed in 5-1 were transformed with plasmids expressing these genes to obtain mycosporin-like amino acid-producing strains. The transformation was carried out according to conventionally known methods.
[0068] 5-3. Pre-culture of mycosporine-like amino acid producing strains The glycerol stock of the mycosporine-like amino acid producing strain containing the mycosporine-like amino acid biosynthesis enzyme gene prepared in 5-2 was transplanted into 10 mL of medium supplemented with 50 g / L of glucose and cultured with shaking at 30°C and 300 rpm for 3 days.
[0069] 5-4. Main culture of mycosporin-like amino acid producing strains 2.5 mL of pre-culture solution and 47.5 mL of culture medium were added to a 500 mL baffled flask and cultured with shaking at 160 rpm and 30°C for 7 days. During the culture, solutions containing glucose and ammonium sulfate were added as needed to prevent depletion of carbon and nitrogen sources.
[0070] 5-5. Measurement of Synorine Production: 1 mL of culture medium was collected and centrifuged at 15,000 rpm for 10 minutes to obtain the culture supernatant. The amount of synorine in the culture supernatant was measured by UPLC. The UPLC measurement conditions are as shown in Table 13. The amount of synorine produced was converted to the concentration in 50 mL of culture medium, which was the initial amount of culture medium (sinoline measurement value × amount of culture medium at the time of collection (mL) / 50 mL).
[0071] 5-6. Results The results are shown in Table 14. When comparing the production of strains using the TK64 strain as the host for the gene expression plasmid (set to 1) with strains using gene-inactivated strains as the host, the production was 1.3 to 1.6 times higher for each type of inactivated strain.
[0072] According to this disclosure, mycosporine-like amino acids or their precursors can be efficiently produced.
Claims
1. A method for producing mycosporine-like amino acids or their precursors, comprising the steps of: culturing a microorganism capable of producing mycosporine-like amino acids or their precursors; and recovering mycosporine-like amino acids or their precursors from the culture, wherein the function or expression of one or more amino acid metabolic enzymes is reduced or lost in the microorganism.
2. The manufacturing method according to claim 1, comprising the step of purifying the recovered mycosporine-like amino acid or its precursor.
3. The manufacturing method according to claim 1 or 2, wherein one or more amino acid metabolic enzymes are selected from the group consisting of proB, ltaA, cysM, pyrB, sda, purA, aspC, mgl, cysA, and metB.
4. The manufacturing method according to claim 3, wherein the one or more amino acid metabolic enzymes are proB, ltaA, or cysM.
5. The method for producing a mycosporine-like amino acid or a group of genes for enzymes that synthesize its precursor, according to any one of claims 1 to 4.
6. The method for producing a mycosporine-like amino acid or its precursor biosynthetic enzyme gene group comprising demethyl-4-deoxygadusol synthase, O-methyltransferase, and ATP Grasp family enzymes, and comprising one or more selected from the group consisting of D-alanine-D-alanine ligase-like enzymes and non-ribosomal peptide synthases (NRPS).
7. The method for producing a mycosporine-like amino acid or its precursor biosynthetic enzyme gene group comprising at least demethyl-4-deoxygadusol synthase, O-methyltransferase, ATP-grasp family enzymes, and D-alanine-D-alanine ligase-like enzymes, according to claim 5.
8. The method for producing a microorganism according to claim 7, wherein the microorganism is Streptomyces lividan or Streptomyces evermethyls.
9. The method for producing a product according to any one of claims 1 to 8, wherein the mycosporin-like amino acid is cinolin, porphyra-334, mycosporin-lysine-alanine (MGA), or mycosporin-lysine (MG).
10. The method for producing a mycosporine-like amino acid, wherein the precursor is 4-deoxygadusol, sedoheptulose-7-phosphate, or demethyl-4-deoxygadusol.
